REVEAL study: Axatilimab + ruxolitinib achieved 69% ORR in R/R #cGvHD. 🩺
60% of patients reported ≥1 Grade 3 TEAE.
20.5% experienced Grade 4.
Findings from #Tandem26 via @astct.bsky.social @cibmtr.bsky.social
Read the review: https://bit.ly/4cyLJ9o
#Hematology #GvHD #MedicalNews